AXA Investment Managers Paris Form 5 REVELATION BIOSCIENCES / Investment Managers Paris AXA ownership change

SEC Form 5

FORM 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0362
Estimated average burden
hours per response:			1.0

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Form 3 Holdings Reported.

Form 4 Transactions Reported.

1. Name and Address of Reporting Person^*

AXA IM Prime Impact Master Fund I SCA SICAV-RAIF

(Last)

(First)

(Middle)

2-4 RUE EUGENE RUPPERT

(Street)

LUXEMBOURG

L-2453

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
REVELATION BIOSCIENCES, INC. [ REVB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
Former 10% Owner

3. Statement for Issuer's Fiscal Year Ended (Month/Day/Year)
12/31/2022

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned at end of Issuer's Fiscal Year (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common stock	01/10/2022⁽¹⁾		J⁽¹⁾	1,958,984⁽¹⁾	A	$0⁽¹⁾	1,958,984⁽¹⁾	D⁽²⁾⁽³⁾⁽⁴⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

1. Name and Address of Reporting Person^*

AXA IM Prime Impact Master Fund I SCA SICAV-RAIF

(Last)

(First)

(Middle)

2-4 RUE EUGENE RUPPERT

(Street)

LUXEMBOURG

L-2453

(City)

(State)

(Zip)

1. Name and Address of Reporting Person^*

AXA IM Prime Impact GP S.a.r.l

(Last)

(First)

(Middle)

2-4, RUE EUGENE RUPPERT

(Street)

LUXEMBOURG

L-2453

(City)

(State)

(Zip)

1. Name and Address of Reporting Person^*

AXA Investment Managers Paris

(Last)

(First)

(Middle)

6 PLACE DE LA PYRAMIDE

(Street)

PUTEAUX

92800

(City)

(State)

(Zip)

1. Name and Address of Reporting Person^*

AXA INVESTMENT MANAGERS UK Ltd

(Last)

(First)

(Middle)

22 BISHOPGATE

(Street)

LONDON

EC2M 3XJ

(City)

(State)

(Zip)

1. Name and Address of Reporting Person^*

AXA Investment Managers S.A.

(Last)

(First)

(Middle)

6 PLACE DE LA PYRAMIDE

TOUR MAJUNGA

(Street)

PUTEAUX

92800

(City)

(State)

(Zip)

1. Name and Address of Reporting Person^*

AXA S.A.

(Last)

(First)

(Middle)

25 AVENUE MATIGNON

(Street)

PARIS

75008

(City)

(State)

(Zip)

Explanation of Responses:

1. On January 10, 2022, Petra Acquisition, Inc. consummated a business combination with the old Revelation Biosciences, Inc., and the reporting persons became the holders of publicly traded shares of the Common Stock of the new Revelation Biosciences, Inc., pursuant to a registration statement

2. The following parties may be deemed to have the power to vote and direct the disposition of the shares of Common Stock owned by AXA IM Prime Impact Master Fund ISCA SICAV-RAIF (the "Fund"):(a) the Fund owns the shares of Common Stock reported herein, (b) the general partner of the Fund, AXA IM Prime Impact GP S.a.r.l, has appointed AXA Investment Managers Paris S.A. ("AIFM") as the alternative investment fund manager of the Fund to undertake all functions required of an external alternative investment fund manager, (c) the Fund with the consent of AIFM and duly represented by its general partner, AXA IM Prime Impact GP S.a.r.l, has also entered into a delegated portfolio management agreement with AIFM and AXA Investment Managers UK Ltd. ("AXA IM UK") in order to appoint AXA IM UK to act as the portfolio manager of the Fund, (d) AXA Investment Managers S.A. is the sole shareholder of AIFM and AXA IM UK, and (e) AXA S.A. is the controlling shareholder of AXA IM SA.

3. The reporting persons do not believe that they constitute a "group" within the meaning of Rule 13d-5 under the Securities Exchange Act of 1934, as amended, and they do not believe that they are otherwise required to attribute to each other the beneficial ownership of the securities reported herein held by them or by any persons or entities for whom or for which AIFM or AXA IM UK provides investment management services. Each of the reporting persons also disclaims beneficial ownership of these securities except to the extent of that person's pecuniary interest therein.

4. On July 28, 2022, the issuer closed a public offering, and, as a result of the dilutive effect of the public offering, the reporting persons ceased to beneficially own more than 10% of the issuer's Common Stock outstanding as of the close of business on July 28, 2022.

	/s/ Mirko Dietz Board Member, AXA IM Prime Impact GP S.a.r.l	02/14/2023
	/s/ Paul Guillaume Board Member, AXA IM Prime Impact GP S.a.r.l	02/14/2023
	/s/ Mirko Dietz Board Member, AXA IM Prime Impact GP S.a.r.l	02/14/2023
	/s/ Paul Guillaume Board Member, AXA IM Prime Impact GP S.a.r.l	02/14/2023
	/s/ Enguerran Six Chief Compliance officer, AXA Investment Managers Paris S.A	02/14/2023
	/s/ Terrance Turner Chief Compliance Officer, AXA Investment Managers UK Ltd	02/14/2023
	/s/ Anthony Gilsoul Attorney-in-fact AXA Investment Managers S.A	02/14/2023
	/s/ Anthony Gilsoul Attorney-in-fact AXA S.A	02/14/2023
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

AXA Investment Managers Paris Form 5REVELATION BIOSCIENCES / Investment Managers Paris AXA ownership change